TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02669017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-402
Description: intravenous infusion
Study: NCT02498639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous balloon aortic valvuloplasty
Description: Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous balloon aortic valvuloplasty
Description: Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded.
Study: NCT04621370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Flat dose of 1500mg delivered intravenously over 30 minutes every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin 85mg/m2 delivered intravenously as per institutional standard on Day 1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil bolus 400mg/m2 delivered intravenously as per institutional standard on D1 of mFOLFOX6 treatment every 2 weeks.~5-fluorouracil infusion 2400mg/m2 delivered intravenously over 46 hours continuously as per institutional standard following bolus 5-fluorouracil.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Radiotherapy (Arm A)
Description: 25 Gray of photon radiation treatment delivered over 5 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long course chemoradiation (Arm B)
Description: 50 Gray of photon radiation treatment delivered over 25 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
Study: NCT02018822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urethane dimethacrylate
Description: Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TPH3
Description: light-cured resin composite for teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esthet-X HD
Description: light cured resin composite for teeth made by Dentsply Caulk
Study: NCT00152542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: 1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No iNO given for days 1-7
Study: NCT00811135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 bid po on days 1-14 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
Study: NCT00428974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 1mg
Description: CF101 1 mg q12 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2mg
Description: CF101 2 mg q12 hours for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 4mg
Description: CF101 4 mg q12 hours for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets q12 hours for 12 weeks
Study: NCT03335332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
Study: NCT00832728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard hospital protocol for the treatment of acute liver failure

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard hospital protocol for the treatment of acute liver failure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAD®
Description: ELAD therapy
Study: NCT03239821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 deflated
Description: deflation balloon

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 deflated
Description: deflation balloon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate
Description: 58.8 mg codeïne phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate
Description: 58.8 mg codeïne phosphate

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sirupus Simplex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sirupus Simplex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 inflated
Description: VIPUN Balloon Catheter 0.1 inflated

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 inflated
Description: VIPUN Balloon Catheter 0.1 inflated
Study: NCT03509350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C Placebo
Description: A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine Placebo
Description: A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone Placebo
Description: A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
Study: NCT03798821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)
Description: six weeks of consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)
Description: six weeks of consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin and sucrose (PLACEBO)
Description: six weeks of consumption
Study: NCT00649532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets 24 mg
Description: 24mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran® Tablets 24 mg
Description: 24mg, single dose fasting
Study: NCT02983682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
Study: NCT04529759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
Study: NCT04373031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX 2
Description: IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
Study: NCT01018875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: Subjects will take 4 capsules once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: Subjects will take 4 capsules once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Subjects will take 4 capsules once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take 4 capsules once daily for 12 weeks.
Study: NCT04429178

Intervention type: OTHER
Intervention: ultrasound
Description: portal vein pulsatility fraction (percent) measured with ultrasound

Intervention type: OTHER
Intervention: ultrasound
Description: portal vein pulsatility fraction (percent) measured with ultrasound

Intervention type: OTHER
Intervention: ultrasound
Description: portal vein pulsatility fraction (percent) measured with ultrasound

Intervention type: OTHER
Intervention: ultrasound
Description: portal vein pulsatility fraction (percent) measured with ultrasound
Study: NCT02305355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acids ethylesters 90 4g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
Study: NCT01866007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (lyophilized formulation)
Description: Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation with PFS-U)
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation with PFS FID)
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation)
Description: Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
Study: NCT00723970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Extended Release
Description: Quetiapine XR, 150-300 mg QHS, for 8 weeks
Study: NCT00429858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
Study: NCT00097760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
Study: NCT03174132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane Lidocaine
Description: Intradermal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Perlane
Description: Intradermal injection
Study: NCT03031301

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrant capsule
Description: One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham capsule
Description: One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
Study: NCT00514865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2333Ms Experimental 2
Description: 5-10 mg QD(once a day) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg QD(once a day) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2333Ms Experimental 1
Description: 1-2 mg QD(once a day) for 8 weeks
Study: NCT00907400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: oral tablet
Study: NCT03616938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation
Description: 2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation
Description: 2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation
Description: 2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
Study: NCT03389035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARCIK-CD19
Description: Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
Study: NCT00896311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Nitroglycerin
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study: NCT00969449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium, (BAY H6689)
Description: One dose of Naproxen sodium extended release 660 mg under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprelan, (BAY H6689)
Description: One dose of Naprelan 500 mg (2 tablets) under fasting conditions
Study: NCT03729492

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CTEPH/CTED work-up
Description: Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
Study: NCT04884230

Intervention type: PROCEDURE
Intervention: Oversewing
Description: Oversewing of the gastric remnant
Study: NCT01451710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
Study: NCT02499068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
Study: NCT00397826

Intervention type: DRUG
Group type: OTHER
Intervention: MK0733
Description: Duration of Treatment: 12 Weeks
Study: NCT01849172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually.
Study: NCT03401528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is an investigational drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is an investigational drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT00825565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alwextin cream
Description: Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
Study: NCT00525395

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Sequential phototherapy
Description: Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous phototherapy
Description: Group B: 6 months non-stop treatment.
Study: NCT04283695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7 or [14C] GX-I7
Description: IM GX-I7 or IV/IM microdose of GX-I7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7 or [14C] GX-I7
Description: IM GX-I7 or IV/IM microdose of GX-I7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7 or [14C] GX-I7
Description: IM GX-I7 or IV/IM microdose of GX-I7
Study: NCT01598038

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Blood sample
Description: Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation